DELIVER
2022
Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved-EF Heart Failure
In 6,263 patients with heart failure and an ejection fraction > 40 %, dapagliflozin reduced worsening heart failure or cardiovascular death compared with placebo.
Result
Efficacy: Worsening HF or CV deathHR 0.82
Below 1 favours dapagliflozin, above 1 favours placebo.
- Absolute difference
- 3.1 points
The absolute difference is derived from the event rates.
Also reported: Benefit consistent across the EF spectrum.
- Subtopic
- SGLT2 inhibitors
- Design
- Double-blind RCT
- Relevance
- Important: one of several pillars.
- Source
- Solomon SD, et al. N Engl J Med. 2022;387(12):1089-1098.doi 10.1056/NEJMoa2206286
Discussion & critique
With EMPEROR-Preserved, made SGLT2 inhibitors the first broadly effective HFpEF therapy. Driven by HF events; mortality not significantly reduced.